Use of avermectin derivative for increasing bioavailability and efficacy of macrocyclic lactones
US11021508B2 · kind B2 · utility
0Cited by
32References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 24, 2018 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | May 24, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D493/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyl, (ii) X represents —CH2—CH2—, or —CH═CH—, (iii) R2 is chosen from or an OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.